If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksItaconix Plc Regulatory News (ITX)

Share Price Information for Itaconix Plc (ITX)

Share Price is delayed by 15 minutes
Get Live Data
109.50    0.00 (0.00%)
Bid:
107.00
Ask:
112.00
Spread: 5.00 (4.673%)
Market Cap: £14.77m
ITX Live PriceLast checked at - London Stock Exchange

Intraday Itaconix Plc Share Chart

H1 2024 Trading Update

16 Jul 2024 07:00

RNS Number : 4931W
Itaconix PLC
16 July 2024
 

For release: 07.00, 16 July 2024

 

Itaconix plc

("Itaconix" or the "Company")

H1 2024 Trading Update

Itaconix (AIM: ITX) (OTCQB: ITXXF), a leading innovator in sustainable plant-based polymers used to decarbonise everyday consumer products, provides the following trading update for the first half of 2024.

Strategic Focus and Commercial Progress

The Company is pleased to report that the Board's expectations for FY 2024 results remain in line with those set out in the announcement of 2 April 2024.

With the strategic decision to decline low-margin business, the Company achieved unaudited revenues of $2.8 million for the first six months of 2024, compared to $4.0 million for the first half of 2023. Unaudited total gross profit margin for the first six months exceeded 38%, compared to 28% for the first six months of 2023 and 31% for FY 2023, reflecting the Company's commitment to enhance profitability. 

In addition to improving gross profit margins, the Company is diversifying its revenue base with new accounts and growth from existing accounts. Initial orders were received in the first six months for a new dish detergent application in Europe, a new sustainable leather account, and a new application in mineral processing. As previously disclosed, revenues and volume growth from these new accounts are expected to occur predominantly in H2 2024 and beyond.

The Company also continues to benefit from new orders and continuing revenues at lower levels from the existing merchandizing customer that the Company had previously taken the decision to decline low margin revenues from.

Financial Position

The Company's balance sheet remains strong, providing sufficient cash to focus on the next generation of customers, applications, and products. Net unaudited cash and investments as at 30 June 2024 were $8.0 million ($10.0 million at 31 December 2023). Cash use reflected higher finished goods inventories, higher accounts receivable in Europe, and new investments in upgrades to its facilities in Stratham, New Hampshire to support revenue growth.

This financial position is allowing the Company to target higher revenue growth and invest in new product development. The Company is seeing many exciting opportunities to develop new ingredients and increase revenues, positioning itself to better capture the commercial value of its performance ingredients.

New Product Launches

The Company launched two new products on 29 April 2024. Itaconix TSI 422, an advanced version of its leading Itaconix TSI 322 product, offers improved performance, lower overall formulation costs, and more compact formulations in cleaning applications. The Company had revenues in the first half from three customers for the use of this new polymer in two North American dish detergent brands and expects to add at least two more brands in H2 2024.

Itaconix ONZ 405, a powder version of the Company's current liquid odour neutraliser, meets customer needs in powder formulations, particularly in laundry and hygiene applications. The Company expects new revenues from this product in H2 2024.

Environmental and Regulatory Progress

The Company completed studies expanding the data on the biodegradability of its water-soluble polymers and advanced global regulatory acceptance with new approvals in China, Australia, and New Zealand. These approvals are expected to generate new revenue opportunities for current and prospective customers.

Financial Outlook

With these results for the first six months of 2024, the Board reiterates its revenue expectations of $6 million to $6.5 million and gross profit margin expectations of 36% for FY 2024.

Further details on first half results will be provided in the 2024 interim report, which the Company plans to release in early September 2024.

John R. Shaw, CEO of Itaconix, commented:

"Enhancing our revenue structure and increasing gross profit margins, while diversifying our revenue streams, pave the way for our next stage of growth. We are positioning ourselves to better capture the commercial value of our performance ingredients with new orders, new volumes in non-detergent uses, and important new product development initiatives. I believe the strategic efforts we are taking now will advance our long-term revenue growth and profitability objectives.

"We remain highly optimistic about our future and commercial progress. We are securing new detergent customers in Europe and North America and expanding the use of our performance ingredients into new applications. These efforts are focused on building a more diverse, profitable, and sustainable revenue base to achieve our goal of being a large and profitable specialty ingredient company."

-Ends-

 

Itaconix plc

John R. Shaw / Laura Denner

+1 603 775-4400

Belvedere Communications

John West / Llew Angus

+44 (0)20 7653 8702

Canaccord Genuity - Nominated Adviser and Sole Broker

Adam James / Harry Pardoe

+44 (0) 20 7523 8000

 

About Itaconix

Itaconix uses its proprietary plant-based polymer technology platform to produce and sell specialty ingredients that improve the safety, performance, and sustainability of consumer products. The Company's current ingredients are enabling and leading new generations of products in cleaning, hygiene, and beauty.

www.itaconix.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFFFEIDVIELIS
Date   Source Headline
15th May 20151:17 pmRNSHolding(s) in Company
11th May 20157:05 amRNSDirector Declaration
5th May 20157:01 amRNSDirector/PDMR Shareholding
13th Apr 20157:00 amRNSNotice of AGM
30th Mar 20157:00 amRNSPreliminary Results
24th Mar 20157:15 amRNSDirector Declaration
9th Jan 20157:00 amRNSBlocklisting Interim Review
5th Jan 201512:00 pmRNSTotal Voting Rights
11th Dec 20147:00 amRNSHolding(s) in Company
10th Nov 20147:00 amRNSPatent Infringement Settled and Discontinued
10th Oct 20144:22 pmRNSTotal Voting Rights
29th Sep 20147:00 amRNSInterim Results
25th Sep 20147:00 amRNSGlobal licence signed with Solvay
26th Aug 20147:00 amRNSNew CEO start date confirmed
9th Jul 20147:00 amRNSBlocklisting Interim Review
4th Jul 20147:00 amRNSAppointment of Chief Executive Officer
2nd Jul 20147:00 amRNSTotal Voting Rights
23rd Jun 20147:01 amRNSNotification of Major Interest in Shares
23rd Jun 20147:00 amRNSNotification of Major Interest in Shares
9th Jun 20147:00 amRNSUS supply agreement for nicotine chewing gum
3rd Jun 20147:00 amRNSTotal Voting Rights
22nd May 201412:34 pmRNSResult of AGM
30th Apr 20143:16 pmRNSNotification of Major Interest in Shares
24th Apr 20147:00 amRNSAward under Long Term Incentive Plan
23rd Apr 201412:45 pmRNSNotification of Major Interest in Shares
23rd Apr 20147:00 amRNSNotice of AGM
22nd Apr 201411:58 amRNSTotal Voting Rights
14th Apr 20147:00 amRNSAward of Technology Strategy Board funding
31st Mar 20147:00 amRNSPreliminary Results
3rd Mar 20147:00 amRNSTotal Voting Rights
30th Jan 201411:39 amRNSBlock Listing
27th Jan 20147:00 amRNSDirectorate Change
24th Jan 20144:46 pmRNSHolding(s) in Company
10th Jan 20147:00 amRNSBlock Listing Six Monthly Return
20th Nov 20137:00 amRNSMarketing approval of nicotine gum in Europe
17th Oct 20137:00 amRNSSupply and Distribution Agreement with Amma Polska
11th Oct 20137:00 amRNSDirector/PDMR Shareholding and Total Voting Rights
25th Sep 20137:00 amRNSInterim Results
1st Aug 20137:00 amRNSTotal Voting Rights
22nd Jul 20137:00 amRNSAward of contract to supply nicotine gum
15th Jul 201312:20 pmRNSChange of Registered Office
9th Jul 20137:00 amRNSBlocklisting Interim Review
28th May 20132:02 pmRNSResult of AGM
17th Apr 20134:47 pmRNSHolding(s) in Company
17th Apr 20137:00 amRNSDirector's Dealings
9th Apr 20137:00 amRNSPositive test results for encapsulation technology
22nd Mar 20137:00 amRNSNotice of AGM and Posting of Annual Report
13th Mar 20137:00 amRNSPreliminary Results
1st Mar 20137:00 amRNSTotal Voting Rights
1st Feb 20132:42 pmRNSNotice of patent infringement proceedings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.